CD8A and neoplasm: The engagement of inhibitory Siglecs by tumour‐associated sialoglycans can suppress immune cell effector functions, such as the cytotoxic activity of NK cells [49] and CD8+ T cells, inhibit phagocytosis by macrophages, impair antigen presentation by dendritic cells [50, 51], and modulate B cell responses.